U.S. markets open in 1 hour 32 minutes

Intra-Cellular Therapies, Inc. (ITCI)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
54.09+0.87 (+1.63%)
At close: 04:00PM EST
54.12 +0.03 (+0.06%)
After hours: 07:41PM EST

Intra-Cellular Therapies, Inc.

430 East 29th Street
New York, NY 10016
United States
646 440 9333

IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees512

Key Executives

NameTitlePayExercisedYear Born
Dr. Sharon Mates Ph.D.Co-Founder, Chairman, CEO & Pres2.25M322.26k1953
Mr. Lawrence J. Hineline CPA, CPASr. VP of Fin., CFO, Treasurer & Assistant Sec.791.01k5.39M1956
Mr. Michael I. Halstead J.D.Exec. VP, Gen. Counsel & Sec.1.08M5.51M1973
Dr. Suresh K. Durgam M.D.Exec. VP & Chief Medical Officer1.03MN/A1969
Mr. Mark NeumannEVP & Chief Commercial Officer1.01MN/A1963
Dr. Robert E. Davis Ph.D.Sr. VP & Chief Scientific OfficerN/AN/A1951
Mr. Juan Fernando SanchezVP of Corp. Communications & Investor RelationsN/AN/A1971
Ms. Karen Patruno Sheehy Esq.Sr. VP & Chief Compliance OfficerN/AN/A1962
Dr. Michael OlchaskeySr. VP & Head of Regulatory AffairsN/AN/AN/A
Mr. John A. BardiSr. VP of Market Access, Policy & Gov. AffairsN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Corporate Governance

Intra-Cellular Therapies, Inc.’s ISS Governance QualityScore as of December 1, 2022 is 6. The pillar scores are Audit: 7; Board: 7; Shareholder Rights: 7; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.